Effects of Inhaled Corticosteroids, Leukotriene Receptor Antagonists, or Both, Plus Long-Acting β2-Agonists on Asthma Pathophysiology: A Review of the Evidence

被引:19
作者
A. Maurizio Vignola
机构
[1] Institute of Respiratory Disease, University of Palermo and IBIM, CNR, Palermo
关键词
Budesonide; Fluticasone Propionate; Salmeterol; Montelukast; Triamcinolone Acetonide;
D O I
10.2165/00003495-200363002-00004
中图分类号
学科分类号
摘要
Chronic inflammation and smooth muscle dysfunction are consistent features of asthma, and are responsible for disease progression and airway remodelling. The development of chronic airway inflammation depends upon the recruitment and activation of inflammatory cells and the subsequent release of inflammatory mediators, including cytokines. Cellular and histological evaluation of drugs with anti-inflammatory activity, such as inhaled corticosteroids (ICSs), is achieved by analysing samples of lung tissue or biological fluids, obtained by techniques such as bronchial biopsy, bronchoalveolar lavage and sputum induction. These provide valuable information on the inflammatory processes occurring in the lung, although not all are equal in value. The beneficial effects of ICSs in asthma treatment are a consequence of their potent and broad anti-inflammatory properties. Furthermore, there have been promising results indicating that ICSs can reverse some of the structural changes that contribute to airway remodelling. Long-acting β2-agonists (LABAs) added to ICSs provide greater clinical efficacy than ICSs alone, suggesting the possibility of complementary activity on the pathophysiological mechanisms of asthma: inflammation and smooth muscle dysfunction. Leukotrienes play a part in the pathogenesis of asthma. Leukotriene receptor antagonists (LTRAs) directly inhibit bronchoconstriction and may have some anti-inflammatory effects, although the extent to which inhibiting one set of inflammatory mediators attenuates the inflammatory response is questionable. In concert with their effect on a broad variety of inflammatory mediators and cells, treatment with ICSs (including ICSs and LABAs) results in superior control of the pathophysiology of asthma and superior clinical efficacy as assessed by the greater improvements in pulmonary function and overall control of asthma compared with LTRAs.
引用
收藏
页码:35 / 51
页数:16
相关论文
共 87 条
[1]  
Chetta A., Foresi A., Del Donno M., Et al., Airways remodeling is a distinctive feature of asthma and is related to severity of disease, Chest, 111, pp. 852-857, (1997)
[2]  
Bousquet J., Jeffery P.K., Busse W.W., Et al., Asthma: From bronchoconstriction to airways inflammation and remodeling, Am J Respir Crit Care Med, 161, pp. 1720-1745, (2000)
[3]  
Johnson M., Combination therapy for asthma: Complementary effects of long-acting β<sub>2</sub>-agonists and corticosteroids, Curr Allergy Clin Immunol, 15, pp. 16-22, (2002)
[4]  
Ward C., Pais M., Bish R., Et al., Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma, Thorax, 57, pp. 309-316, (2002)
[5]  
Vignola A.M., La Grutta S., Chiappara G., Et al., Cellular network in airways inflammation and remodelling, Paediatr Respir Rev, 3, pp. 41-46, (2002)
[6]  
Smith L.J., Comparative efficacy of inhaled corticosteroids and antileukotriene drugs in asthma, BioDrugs, 15, pp. 239-249, (2001)
[7]  
Elias J.A., Airway remodeling in asthma: Unanswered questions, Am J Respir Crit Care Med, 161, (2000)
[8]  
Jeffery P.K., Laitinen A., Venge P., Biopsy markers of airway inflammation and remodelling, Respir Med, 94, SUPPL. F, pp. 9-15, (2000)
[9]  
Kanniess F., Richter K., Bohme S., Et al., Montelukast vs fluticasone: Effects on lung function, airway responsiveness and inflammation in moderate asthma, Eur Respir J, 20, pp. 853-858, (2002)
[10]  
Expert Panel Report 2. Guidelines for the Diagnosis and Management of Asthma, (1997)